The generics industry has undergone significant change over the last five years, with a wave of consolidation altering the competitive landscape. Indeed, the intense merger and acquisition activity has lead to more diverse companies, both on a product level and geographically, with pure generics companies becoming increasingly rare.

• Detailed profiles of the leading fifteen companies involved in the generics industry
• Benchmarking analysis of the leading companies' financial performance in 2005
• Assessment of and comment on the business models in the generics market
• Overviews of company strategy and alliance networks


Highlights



Within the generics segment, there is increasing diversity in companies' offerings, with a variety of commodity, specialty, branded and super generics being offered. In addition, some generics companies are now involved in proprietary product research and development or in-licensing.





Several generics companies have demonstrated strong growth between 2004 and 2005. This has primarily been driven by acquisitions, although organic growth has also boosted sales. In contrast, many of the companies that have not participated in the wave of consolidation within the generics market have posted stagnant or declining sales and profits.





Teva and Sandoz are currently the leading companies by sales, and these positions will be bolstered by the consolidation of their recent acquisitions. Watson and Actavis will see their market share increase if their planned acquisitions of Andrx and Pliva, respectively, are successfully completed.



Reasons to Purchase


• Identify the leading companies within the generics market in 2005 and their strategies for the future
• Understand the changing competitive dynamics within the generics industry
• Assess the different business models being applied in the generics industry and the success of each one